Karen Bick Sells 5,485 Shares of Ralliant (NYSE:RAL) Stock

Ralliant Corporation (NYSE:RAL) SVP Karen Bick sold 5,485 shares of the firm’s stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $45.00, for a total value of $246,825.00. Following the transaction, the senior vice president directly owned 46,756 shares in the company, valued at $2,104,020. This trade represents a 10.50% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this link.

Ralliant Price Performance

Shares of NYSE RAL opened at $44.74 on Friday. The stock has a market cap of $5.00 billion and a P/E ratio of 22.83. The firm’s 50-day simple moving average is $48.94 and its 200 day simple moving average is $46.64. Ralliant Corporation has a fifty-two week low of $37.27 and a fifty-two week high of $57.02. The company has a quick ratio of 0.58, a current ratio of 0.84 and a debt-to-equity ratio of 0.38.

Ralliant (NYSE:RAL) last announced its earnings results on Wednesday, February 4th. The company reported $0.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.67 by $0.02. The company had revenue of $554.60 million during the quarter, compared to the consensus estimate of $543.04 million. The company’s revenue was up 1.2% on a year-over-year basis. Ralliant has set its Q1 2026 guidance at 0.460-0.520 EPS and its FY 2026 guidance at 2.220-2.420 EPS.

Ralliant Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 23rd. Stockholders of record on Monday, March 9th will be issued a $0.05 dividend. The ex-dividend date is Monday, March 9th. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. Ralliant’s dividend payout ratio (DPR) is 10.20%.

Analysts Set New Price Targets

Several equities research analysts recently commented on the company. Citigroup dropped their target price on Ralliant from $61.00 to $51.00 and set a “buy” rating on the stock in a report on Friday, February 6th. Morgan Stanley reaffirmed an “overweight” rating and set a $45.00 price target on shares of Ralliant in a research note on Friday, February 6th. Truist Financial lowered their price target on Ralliant from $62.00 to $49.00 and set a “buy” rating on the stock in a research report on Friday, February 6th. Royal Bank Of Canada dropped their price objective on Ralliant from $52.00 to $41.00 and set a “sector perform” rating on the stock in a research note on Friday, February 6th. Finally, Barclays cut their price objective on Ralliant from $60.00 to $52.00 and set an “overweight” rating for the company in a report on Monday, February 9th. Seven equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $50.50.

Institutional Trading of Ralliant

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. boosted its holdings in Ralliant by 10.7% during the third quarter. Vanguard Group Inc. now owns 14,589,423 shares of the company’s stock worth $637,995,000 after buying an additional 1,415,327 shares in the last quarter. Dodge & Cox grew its position in Ralliant by 13.3% in the fourth quarter. Dodge & Cox now owns 12,214,679 shares of the company’s stock worth $621,849,000 after buying an additional 1,434,376 shares during the last quarter. Viking Global Investors LP bought a new position in shares of Ralliant in the second quarter valued at $257,200,000. Millennium Management LLC increased its holdings in shares of Ralliant by 172.4% in the fourth quarter. Millennium Management LLC now owns 4,973,001 shares of the company’s stock valued at $253,175,000 after buying an additional 3,147,660 shares in the last quarter. Finally, State Street Corp acquired a new stake in shares of Ralliant during the 2nd quarter valued at $213,096,000.

About Ralliant

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.